This report, published by the Center for Strategic & International Studies (CSIS) on Tuesday and titled “The Private-Sector Role in Public Health,” reflects on an evolution in the roles and responsibilities of business in global health over the recent decades. “Private-sector engagement was among the main issues addressed at the recent 4th High Level Forum for Aid Effectiveness in Busan, Korea,” CSIS writes on its website, adding, “[A]s Lars Thunell, executive vice president and CEO of the International Finance Corporation (IFC), observed, ‘This could be the turning point where we recognize the mutually supportive roles of the private and public sectors in promoting development’” (Sturchio/Goel, 1/31).
Private Sector Involvement
This post on the Center for Strategic & International Studies’ “Smart Global Health” blog reports on a presentation hosted by the Global Health Policy Center on Monday which “highlight[ed] the contributions faith-based-organizations (FBOs) make to global health, including the fight against HIV/AIDS.” The post highlights quotes from several speakers at the event, provides audio footage of the event, and links to podcast interviews with Kay Warren, founder of the HIV/AIDS Initiative at Saddleback Church, and Ken Hackett, president of Catholic Relief Services (1/31).
The announcement at the end of January of the largest coordinated effort to fight neglected tropical diseases (NTDs) provides “more reason to hope that we may soon see a future free of these diseases,” Adetokunbo Lucas, former director of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, writes in a Daily Monitor opinion piece. “This new coordinated action will take these previous efforts to a whole new level,” he writes, adding, “Together, these partners have pledged to increase the supply of existing drugs and invest and collaborate on research to accelerate the development of new and better drugs.”
In her “Global Health Blog,” Guardian health editor Sarah Boseley speaks with GlaxoSmithKline CEO Andrew Witty about the year-long efforts to bring together the heads of more than a dozen pharmaceutical companies in a large public-private initiative to control or eliminate neglected tropical diseases (NTDs). “In terms of what should this industry be doing preferentially, it should be making available the drugs which nobody else has for people in these countries who suffer from these diseases … and we should be committing ourselves to discover more, better drugs for the future, and we’re doing that today and we’re collaborating with others to make it happen quicker,” Witty said (1/31).
In this post in IntraHealth International’s “Global Health” blog, Editorial Manager Susanna Smith responds to an editorial published in the Lancet earlier this month that “issued a dire warning to the international medical community” about the use of medicine as a weapon of war in Syria, writing, “It is just the latest in a series of reports from across the Middle East on how medical care and medical professionals and facilities are being used to inflict politically motivated violence.” She adds, “The U.N.’s condemnation of this type of violence in Syria specifically is one step in the right direction, but it is high time the international medical community speaks out against the overt violations of medicine’s covenant with society, violations that are clearly a strategic weapon on the part of these political regimes” (2/27).
Pharmaceutical company Novartis “has spoken out following criticism about its challenge to India’s patent laws, insisting that access to life-saving drugs is not under peril by the move,” Pharma Times World News reports. The case, which the Indian Supreme Court is scheduled to hear next month, challenges “Indian patent law, notably Section 3(d), which states that a modification of a known chemical composition is non-patentable,” the news service writes.
In this guest post in the Center for Global Health Policy’s “Science Speaks” blog, Brook Baker of the Northeastern University School of Law Program on Human Rights and the Global Economy, “describe[s] and comment[s] on pharmaceutical company Novartis’s court challenge to India’s strict standards of patenting medicine” and worldwide protests against the company that took place last week prior to its shareholder meeting (Mazzotta, 2/27).
Pharma Companies Improving Access To Medicines But Lack Oversight Of Outsourced Clinical Trials, Analysis Says
Pharmaceutical companies are showing “greater accountability in the boardroom today over access to medicines, with more openness, targets and investment in drugs relevant to the poor,” but they “show no evidence that they adequately supervise the conduct of outsourced clinical drug trials, according to a new analysis released on Wednesday,” the Financial Times reports (Jack, 11/28). Published every two years, the Access to Medicine Index “ranks the world’s 20 biggest drug companies,” BBC News notes, adding, “GlaxoSmithKline remains at the top of the index, followed closely by Johnson & Johnson and Sanofi.”
AllAfrica correspondent Cindy Shiner recently interviewed Vanessa Kerry, CEO of the Global Health Service Corps, at the annual meeting of the American Society of Tropical Medicine and Hygiene taking place in Atlanta this week. Next year, volunteer doctors and nurses will travel through the Service Corps to Tanzania, Malawi, and Uganda to work in partnership with the Peace Corps, according to AllAfrica. In the interview, Kerry said the program grew out of a desire on the part of physicians and other health care workers to help in resource-poor countries, as well as calls from those countries for more U.S. assistance in building health system capacity. Kerry discusses the focus of the program, how it works as a private partner with public programs, and how the first countries were chosen (11/13).
Wall Street Journal Examines Program In Pakistan Looking To Provide Health Insurance For Poor Urban Residents
The Wall Street Journal examines how “some local social entrepreneurs are coming up with new ideas to provide the poor with access to better medical services” in Pakistan, where the health care system is “split between low-cost government-funded hospitals offering basic services and expensive private-sector medical institutions … [b]ut the majority of the country’s 190 million people have little access to health care.” The newspaper describes how one program, called Naya Jeevan — “a non-profit micro-insurance program for the urban poor” that “offers an insurance program at subsidized rates under a national group health-insurance model” — operates to help ensure affordable medical care for the poor and how it has come “under scrutiny from the country’s insurance regulator” (Bahree, 11/6).